NICE has published new guidance approving the use radio frequency ablation for the eradication of dysplastic Barrett’s oesophagus. Barrett’s oesophagus is a condition characterised by abnormal epithelium.
In some patients, Barrett’s oesophagus may progress, through metaplasia and dysplasia to oesophageal adenocarcinoma. “The UK has one of the highest concentrations of Barrett’s oesophagus in the world. Until now, oesophagectomy has been the standard of care,” noted Dr Laurence Lovat, senior lecturer and consultant gastroenterologist at the University College Medical School, London. The first to use RFA in the UK, Dr Lovat added: “We think radio frequency ablation will play an important role in the endoscopic management of our patients.” Greg Barrett, president and chief executive officer at Bârrx, (a supplier of radio frequency ablation systems) said: “NICE represents one of the most rigorous health technology assessment groups in the world. We are pleased that their guidance supports the use of radio frequency ablation for patients with this particularly high risk type of dysplasia.”
